Share
𝕏 Facebook LinkedIn

Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach

PAPER manual J Exp Clin Cancer Res 2009 Other Effect: mixed Evidence: Very low

Abstract

Purpose: Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer. Patients and methods: We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options. Results: We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57-92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver). Conclusion: Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer. Trial registration: clinicaltrials.gov identifier NCT00805337.

AI evidence extraction

At a glance
Study type
Other
Effect direction
mixed
Population
Patients with various types of cancer; compassionate treatment in patients with advanced cancer and limited therapeutic options
Sample size
163
Exposure
ELF therapeutic device/systemic delivery (amplitude-modulated electromagnetic fields)
Evidence strength
Very low
Confidence: 74% · Peer-reviewed: yes

Main findings

Using a noninvasive biofeedback method, 1524 frequencies (0.1 Hz to 114 kHz) were identified in 163 cancer patients, with most frequencies (57–92%) reported as specific to a single tumor type. Compassionate treatment was offered to 28 patients; among 13 evaluable for response, 1 complete response (11 months), 1 partial response (13.5 months), and 4 cases of stable disease (4.0 to >34.1 months) were reported. Toxicity was limited to grade 1 fatigue in three patients, with no grade 2–4 toxicities reported.

Outcomes measured

  • Identification of tumor-specific frequencies
  • Adverse events/toxicity (NCI grading)
  • Tumor response (complete response, partial response, stable disease)
  • Feasibility/tolerability of administering tumor-specific frequencies

Limitations

  • Noninvasive biofeedback method used to identify frequencies; details not provided in abstract
  • Compassionate-use treatment without stated control group
  • Only 13/28 treated patients were evaluable for response
  • Heterogeneous cancer types and metastatic sites
  • Duration of exposure/treatment regimen not specified in abstract
  • No SAR or field strength/exposure metrics reported in abstract
View raw extracted JSON
{
    "study_type": "other",
    "exposure": {
        "band": "ELF",
        "source": "therapeutic device/systemic delivery (amplitude-modulated electromagnetic fields)",
        "frequency_mhz": null,
        "sar_wkg": null,
        "duration": null
    },
    "population": "Patients with various types of cancer; compassionate treatment in patients with advanced cancer and limited therapeutic options",
    "sample_size": 163,
    "outcomes": [
        "Identification of tumor-specific frequencies",
        "Adverse events/toxicity (NCI grading)",
        "Tumor response (complete response, partial response, stable disease)",
        "Feasibility/tolerability of administering tumor-specific frequencies"
    ],
    "main_findings": "Using a noninvasive biofeedback method, 1524 frequencies (0.1 Hz to 114 kHz) were identified in 163 cancer patients, with most frequencies (57–92%) reported as specific to a single tumor type. Compassionate treatment was offered to 28 patients; among 13 evaluable for response, 1 complete response (11 months), 1 partial response (13.5 months), and 4 cases of stable disease (4.0 to >34.1 months) were reported. Toxicity was limited to grade 1 fatigue in three patients, with no grade 2–4 toxicities reported.",
    "effect_direction": "mixed",
    "limitations": [
        "Noninvasive biofeedback method used to identify frequencies; details not provided in abstract",
        "Compassionate-use treatment without stated control group",
        "Only 13/28 treated patients were evaluable for response",
        "Heterogeneous cancer types and metastatic sites",
        "Duration of exposure/treatment regimen not specified in abstract",
        "No SAR or field strength/exposure metrics reported in abstract"
    ],
    "evidence_strength": "very_low",
    "confidence": 0.7399999999999999911182158029987476766109466552734375,
    "peer_reviewed_likely": "yes",
    "keywords": [
        "amplitude-modulated electromagnetic fields",
        "tumor-specific frequencies",
        "biofeedback",
        "compassionate treatment",
        "advanced cancer",
        "0.1 Hz",
        "114 kHz",
        "feasibility",
        "toxicity",
        "clinical response"
    ],
    "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.